HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.

Trial Details

NCT ID
NCT06112704
Phase
PHASE2
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • HS-20093
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Fujian, Fujian, China
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Harbin, Heilongjiang, China|45.75,126.65

Key Eligibility Criteria

  • Men or women aged more than or equal to (≥) 18 years.
  • Histologically or cytologically confirmed, relapsed, locally advanced or metastatic esophageal carcinomas and other advanced solid tumor.
  • At least one extra measurable lesion according to RECIST 1.1 (cavity structures such as oesophagus cannot serve as measurable lesions).
  • Agree to provide fresh or archival tumor tissue and blood samples.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →